⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AGEN News
Agenus Inc.
Agenus ernennt BAP Pharma zum exklusiven globalen Partner für die BOT+BAL-Zugangsprogramme
businesswire.com
AGEN
Agenus désigne BAP Pharma comme partenaire mondial exclusif pour les programmes d’accès à la combinaison BOT+BAL
businesswire.com
AGEN
Samenvatting: Agenus benoemt BAP Pharma tot exclusieve wereldwijde partner voor de BOT+BAL-toegangsprogramma’s
businesswire.com
AGEN
Agenus指定BAP Pharma為BOT聯合BAL療法取得計畫的全球獨家合作夥伴
businesswire.com
AGEN
Agenus 指定 BAP Pharma 为 BOT+BAL 准入项目全球独家合作伙伴
businesswire.com
AGEN
Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026
businesswire.com
AGEN
Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer
businesswire.com
AGEN
Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026
businesswire.com
AGEN
アジーナス、MSSまたはpMMRの転移性大腸がんを対象としたBOT+BAL免疫療法併用のグローバル第3相BATTMAN試験で初の患者登録を発表
businesswire.com
AGEN
Agenus annonce le recrutement du premier patient dans l’essai mondial de phase III BATTMAN portant sur l’association immunothérapeutique BOT+BAL dans le cadre du cancer colorectal métastatique MSS ou pMMR
businesswire.com
AGEN